Catalog No.: PC-72501Not For Human Use, Lab Use Only.
JH-RE-06 is a potent REV1-REV7 interface inhibitor (IC50=0.78 uM, Kd=0.42 uM) that disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ, induces REV1 dimerization and blocks POLζ recruitment.
JH-RE-06 is a potent REV1-REV7 interface inhibitor (IC50=0.78 uM, Kd=0.42 uM) that disrupts mutagenic translesion synthesis (TLS) by preventing recruitment of mutagenic POLζ, induces REV1 dimerization and blocks POLζ recruitment.
JH-RE-06 enhances cisplatin cytotoxicity and suppresses cisplatin-induced mutagenesis by interfering with REV1-dependent mutagenic TLS.
JH-RE-06 sensitizes cells to cisplatin and reduces HPRT mutations in a REV1-dependent manner.
JH-RE-06 (1.6 mg/kg, i.p.) improves tumor cell response to cisplatin in a xenograft mouse model.
JH-RE-06 is a novel TLS inhibitor as a class of chemotherapy adjuvants.
